BACKGROUND AND AIMS: Vitamin D 24-hydroxylase is an enzyme encoded by the CYP24A1 gene, which inhibits the activation of vitamin D to form inactive metabolites. More than 20 currently described pathogenic variants (usually biallelic) of this gene are responsible for idiopathic infantile hypercalcemia manifested typically in childhood (often in newborns) with hypercalcemia, hypercalciuria, and nephrocalcinosis. However, a few patients (mostly with monoallelic heterozygous pathogenic variants) can develop mild symptoms in adulthood. CASE DESCRIPTION: We present the case of a 43-year-old male patient with hypertension and heterozygous Leiden mutation, with mural thrombi in the common iliac artery, who was sent by a nephrologist to endocrinological examination due to hypoparathyroidism, progressive hypercalcemia, hypercalciuria, and CKDG2A1. Complete laboratory and imaging methods (including PET-CT) excluded PTH-related peptide-mediated hypercalcemia and granulomatosis. Finally, the genetic analysis of the CYP24A1 gene revealed the presence of a novel combination of two heterozygous pathogenic variants: CYP24A1: c. 443T>C p.(Leu148Pro) and c.1186C>T p.(Arg396Trp). CONCLUSION: Differential diagnosis of patients with hypercalciuria, nephrocalcinosis, and hypercalcemia related to vitamin D exposure should include the CYP24A1 gene mutation. To the best of our knowledge, this is the first case of the novel combination of two heterozygous pathogenic variants of CYP24A1.

Department of Biology and Medical Genetics 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Department of Internal Medicine Faculty Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Prague Czechia

Nefromed Prague Czechia

Zobrazit více v PubMed

DiMeglio LA, Imel EA. Chapter 13 - calcium and phosphate: hormonal regulation and metabolism. In: Burr DB, Allen MR. editors. Basic and Applied Bone Biology. San Diego, CA: Academic Press; (2014). p. 261–82. 10.1016/B978-0-12-416015-6.00013-7 DOI

Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. (2003) 67:1959–66. PubMed

Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. . Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. (2011) 365:410–21. 10.1056/NEJMoa1103864 PubMed DOI

Carpenter TO. CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations. J Steroid Biochem Mol Biol. (2017) 173:337–40. 10.1016/j.jsbmb.2017.01.006 PubMed DOI

De Paolis E, Scaglione GL, De Bonis M, Minucci A, Capoluongo E. CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype. Clin Chem Lab Med. (2019) 57:1650–67. 10.1515/cclm-2018-1208 PubMed DOI

O'Keeffe DT, Tebben PJ, Kumar R, Singh RJ, Wu Y, Wermers RA. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect. Osteoporosis Int. (2016) 27:3121–5. 10.1007/s00198-016-3615-6 PubMed DOI

Lightwood R, Stapleton T. Idiopathic hypercalcaemia in infants. Lancet. (1953) 262:255–6. 10.1016/S0140-6736(53)90187-1 PubMed DOI

Jacobs TP, Kaufman M, Jones G, Kumar R, Schlingmann K-P, Shapses S, et al. . A lifetime of hypercalcemia and hypercalciuria, finally explained. J Clin Endocrinol Metab. (2014) 99:708–12. 10.1210/jc.2013-3802 PubMed DOI PMC

Jones G, Kottler ML, Schlingmann KP. Genetic diseases of vitamin D metabolizing enzymes. Endocrinol Metab Clin North Am. (2017) 46:1095–117. 10.1016/j.ecl.2017.07.011 PubMed DOI

Molin A, Baudoin R, Kaufmann M, Souberbielle JC, Ryckewaert A, Vantyghem MC, et al. . CYP24A1 mutations in a cohort of hypercalcemic patients: evidence for a recessive trait. J Clin Endocrinol Metab. (2015) 100:E1343–52. 10.1210/jc.2014-4387 PubMed DOI

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. (2015) 17:405–24. 10.1038/gim.2015.30 PubMed DOI PMC

Cappellani D, Brancatella A, Kaufmann M, Minucci A, Vignali E, Canale D, et al. . Hereditary hypercalcemia caused by a homozygous pathogenic variant in the CYP24A1 gene: a case report and review of the literature. Case Rep Endocrinol. (2019) 2019:4982621. 10.1155/2019/4982621 PubMed DOI PMC

Lenherr-Taube N, Young EJ, Furman M, Elia Y, Assor E, Chitayat D, et al. . Mild idiopathic infantile hypercalcemia-part 1: biochemical and genetic findings. J Clin Endocrinol Metab. (2021) 106:2915–37. 10.1210/clinem/dgab431 PubMed DOI PMC

Molin A, Lemoine S, Kaufmann M, Breton P, Nowoczyn M, Ballandonne C, et al. . overlapping phenotypes associated with CYP24A1, SLC34A1, and SLC34A3 mutations: a cohort study of patients with hypersensitivity to vitamin D. Front Endocrinol. (2021) 12:736240. 10.3389/fendo.2021.736240 PubMed DOI PMC

Nesterova G, Malicdan MC, Yasuda K, Sakaki T, Vilboux T, Ciccone C, et al. . 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol. (2013) 8:649–57. 10.2215/CJN.05360512 PubMed DOI PMC

Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. (2012) 523:9–18. 10.1016/j.abb.2011.11.003 PubMed DOI

Kaufmann M, Prosser DE, Jones G. Bioengineering anabolic vitamin D-25-hydroxylase activity into the human vitamin D catabolic enzyme, cytochrome P450 CYP24A1, by a V391L mutation. J Biol Chem. (2011) 286:28729–37. 10.1074/jbc.M111.236679 PubMed DOI PMC

Fencl F, Bláhová K, Schlingmann KP, Konrad M, Seeman T. Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene. Eur J Pediatr. (2013) 172:45–9. 10.1007/s00431-012-1818-1 PubMed DOI

Wolf P, Müller-Sacherer T, Baumgartner-Parzer S, Winhofer Y, Kroo J, Gessl A, et al. . A case of “late-onset” idiopathic infantile hypercalcemia secondary to mutations in the CYP24A1 gene. Endocr Pract. (2014) 20:e91–5. 10.4158/EP13479.CR PubMed DOI

Dinour D, Davidovits M, Aviner S, Ganon L, Michael L, Modan-Moses D, et al. . Maternal and infantile hypercalcemia caused by vitamin-D-hydroxylase mutations and vitamin D intake. Pediatr Nephrol. (2015) 30:145–52. 10.1007/s00467-014-2889-1 PubMed DOI

Figueres ML, Linglart A, Bienaime F, Allain-Launay E, Roussey-Kessler G, Ryckewaert A, et al. . Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am J Kidney Dis. (2015) 65:122–6. 10.1053/j.ajkd.2014.06.037 PubMed DOI

Shah AD, Hsiao EC, O'Donnell B, Salmeen K, Nussbaum R, Krebs M, et al. . Maternal hypercalcemia due to failure of 1,25-dihydroxyvitamin-D3 catabolism in a patient with CYP24A1 mutations. J Clin Endocrinol Metab. (2015) 100:2832–6. 10.1210/jc.2015-1973 PubMed DOI PMC

Cools M, Goemaere S, Baetens D, Raes A, Desloovere A, Kaufman JM, et al. . Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study. Bone. (2015) 81:89–96. 10.1016/j.bone.2015.06.018 PubMed DOI

Jiráčková J, Hyšpler R, Alkanderi S, Pavlíková L, Palicka V. Novel CYP24A1 mutation in a young male patient with nephrolithiasis: case report. Kidney Blood Press Res. (2019) 44: 870–7. 10.1159/000500922 PubMed DOI

Skalova S, Cerna L, Bayer M, Kutilek S, Konrad M, Schlingmann KP. Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia. Iran J Kidney Dis. (2013) 7:160–4. PubMed

St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, et al. . Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology. (2000) 141:2658–66. 10.1210/endo.141.7.7579 PubMed DOI

Colussi G, Ganon L, Penco S, Korneyeva S, Poole L, Saha G, et al. . Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): Implications for mineral metabolism changes in chronic renal failure. Nephrol Dial Transplant. (2014) 29:636–43. 10.1093/ndt/gft460 PubMed DOI

St-Arnaud R. CYP24A1-deficient mice as a tool to uncover a biological activity for vitamin D metabolites hydroxylated at position 24. J Steroid Biochem Mol Biol. (2010) 121:254–6. 10.1016/j.jsbmb.2010.02.002 PubMed DOI

Nguyen M, Boutignon H, Mallet E, Linglart A, Guillozo H, Jehan F, et al. . Infantile hypercalcemia and hypercalciuria: new insights into a vitamin D-dependent mechanism and response to ketoconazole treatment. J Pediatr. (2010) 157:296–302. 10.1016/j.jpeds.2010.02.025s PubMed DOI

Sayers J, Hynes AM, Srivastava S, Dowen F, Quinton R, Datta HK, et al. . Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole. Clin Kidney J. (2015) 8:453–5. 10.1093/ckj/sfv028 PubMed DOI PMC

Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y, et al. . Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab. (2012) 97:E423–7. 10.1210/jc.2011-1935 PubMed DOI PMC

Hawkes CP, Li D, Hakonarson H, Meyers KE, Thumme KE, Levine MA. CYP3A4 Induction by Rifampin: an alternative pathway for Vitamin D inactivation in patients with CYP24A1 mutations. J Clin Endocrinol Metab. (2017) 102:1440–6. 10.1210/jc.2016-4048 PubMed DOI PMC

Siener R, Struwe F, Hesse A. Effect of L-methionine on the risk of phosphate stone formation. Urology. (2016) 98:39–43. 10.1016/j.urology.2016.08.007 PubMed DOI